ArticleMultiple sclerosis journal - experimental, translational and clinical

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.

Dana Horáková et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.